dc.contributor.author |
Berenguer, Juan |
|
dc.contributor.author |
Jarrín, Inmaculada |
|
dc.contributor.author |
Pérez-Latorre, Leire |
|
dc.contributor.author |
Hontañón, Víctor |
|
dc.contributor.author |
Vivancos, María J. |
|
dc.contributor.author |
Navarro, Jordi |
|
dc.contributor.author |
Téllez, María J. |
|
dc.contributor.author |
Guardiola, Josep M. |
|
dc.contributor.author |
Iribarren, José Antonio |
|
dc.contributor.author |
Hernando Jeréz, María Asunción
|
|
dc.contributor.author |
GeSIDA 8514 Study Group |
|
dc.date.accessioned |
2018-02-21T16:45:58Z |
|
dc.date.available |
2018-02-21T16:45:58Z |
|
dc.date.issued |
2018 |
|
dc.identifier.citation |
Berenguer, J., Jarrín, I., Pérez-Latorre, L., Hontañón, V., Vivancos, M. J., Navarro, J., ... & Márquez, M. (2018). Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant. Open Forum Infectious Diseases, 5(1). DOI: 10.1093/ofid/ofx258 |
spa |
dc.identifier.issn |
2328-8957 |
|
dc.identifier.uri |
http://hdl.handle.net/11268/7072 |
|
dc.description.abstract |
Background. We assessed the prevalence of antibodies against hepatitis C virus (HCV-Abs) and active HCV infection in patients
infected with human immunodeficiency virus (HIV) in Spain in 2016 and compared the results with those of similar studies performed
in 2002, 2009, and 2015.
Methods. The study was performed in 43 centers during October–November 2016. The sample was estimated for an accuracy
of 2% and selected by proportional allocation and simple random sampling. During 2016, criteria for therapy based on direct-acting
antiviral agents (DAA) were at least significant liver fibrosis, severe extrahepatic manifestations of HCV, and high risk of HCV
transmissibility.
Results. The reference population and the sample size were 38 904 and 1588 patients, respectively. The prevalence of HCV-Abs
in 2002, 2009, 2015, and 2016 was 60.8%, 50.2%, 37.7%, and 34.6%, respectively (P trend <.001, from 2002 to 2015). The prevalence
of active HCV in 2002, 2009, 2015, and 2016 was 54.0%, 34.0%, 22.1%, and 11.7%, respectively (P trend <.001). The anti-HCV treatment
uptake in 2002, 2009, 2015, and 2016 was 23.0%, 48.0%, 59.3%, and 74.7%, respectively (P trend <.001). In 2016, HCV-related
cirrhosis was present in 7.6% of all HIV-infected individuals, 15.0% of patients with active HCV, and 31.5% of patients who cleared
HCV after anti-HCV therapy.
Conclusions. Our findings suggest that with universal access to DAA-based therapy and continued efforts in prevention and
screening, it will be possible to eliminate active HCV among HIV-infected individuals in Spain in the short term. However, the burden
of HCV-related cirrhosis will continue to be significant among HIV-infected individuals. |
spa |
dc.description.sponsorship |
Fundación SEIMC-GESIDA, Madrid, Spain |
spa |
dc.language.iso |
eng |
spa |
dc.rights |
Attribution-NonCommercial-NoDerivatives 4.0 International |
* |
dc.rights.uri |
https://creativecommons.org/licenses/by-nc-nd/4.0/ |
* |
dc.title |
Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant |
spa |
dc.type |
article |
spa |
dc.description.impact |
3.371 JCR (2018) Q2, 74/158 Immunology, 29/89 Infectious Diseases, 46/133 Microbiology |
spa |
dc.description.impact |
1.480 SJR (2018) Q1, 64/378 Neurology (clinical), 77/381 Oncology |
spa |
dc.description.impact |
No data IDR 2018 |
spa |
dc.identifier.doi |
10.1093/ofid/ofx258 |
|
dc.rights.accessRights |
openAccess |
spa |
dc.subject.uem |
Epidemiología |
spa |
dc.subject.uem |
Hepatitis |
spa |
dc.subject.unesco |
Epidemiología |
spa |
dc.subject.unesco |
Enfermedad |
spa |
dc.description.filiation |
UEM |
spa |
dc.peerreviewed |
Si |
spa |